{"id":"NCT02920008","sponsor":"Astex Pharmaceuticals, Inc.","briefTitle":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","officialTitle":"A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-16","primaryCompletion":"2020-01-20","completion":"2020-06-01","firstPosted":"2016-09-30","resultsPosted":"2023-05-25","lastUpdate":"2024-08-28"},"enrollment":302,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Myeloid Leukemia"],"interventions":[{"type":"DRUG","name":"guadecitabine","otherNames":["SGI-110"]},{"type":"DRUG","name":"Treatment Choice (TC)","otherNames":[]}],"arms":[{"label":"guadecitabine","type":"EXPERIMENTAL"},{"label":"Treatment Choice (TC)","type":"ACTIVE_COMPARATOR"}],"summary":"Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC. TC options include the 8 high or low intensity, locally available regimens below; or Best supportive Care (BSC) alone:\n\n* High intensity (intermediate or high dose cytarabine \\[HiDAC\\]; mitoxantrone, etoposide, and cytarabine \\[MEC\\]; or fludarabine, cytarabine, granulocyte colony stimulating factor \\[G-CSF\\], +/- idarubicin \\[FLAG/FLAG-Ida\\]).\n* Low intensity (low dose cytarabine \\[LDAC\\], decitabine, or azacitidine).\n* BSC.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"From the date of randomization until the date of death, or approximately 34 months","effectByArm":[{"arm":"Guadecitabine","deltaMin":191,"sd":null},{"arm":"Treatment Choice (TC)","deltaMin":163,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.3287"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":95,"countries":["United States","Belgium","Canada","Denmark","France","Germany","Hungary","Italy","Japan","Poland","South Korea","Spain","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["38231126"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":113,"n":145},"commonTop":["Thrombocytopenia","Nausea","Anaemia","Neutropenia","Pyrexia"]}}